U.S. and European Acceptance of Alternative Methods 1998-2009¹ (Arranged by Test Method Evaluation Area)

Acute Dermal Systemic Toxicity

Method	ICCVAM BRDs and Peer Review	U.S. Regulatory Acceptance/ Endorsement	OECD/Other Adoption	EU Regulatory Acceptance/ Endorsement ²
In vitro dermal absorption methods	ICCVAM contributed to U.S. OECD TG review, expert consultation meetings	Yes, as OECD TG 428 in 2004	OECD TG 428 (2004)	Yes, via OECD

Acute Oral Systemic Toxicity

Method	ICCVAM BRDs and Peer Review	U.S. Regulatory Acceptance/ Endorsement	OECD/Other Adoption	EU Regulatory Acceptance/ Endorsement ²
Up and Down Procedure (UDP)	ICCVAM peer review and report; recommended in 2001	Yes, accepted by U.S. in 2003; as OECD TG 425	OECD TG 425 (2001)	Yes, via OECD
Fixed Dose Procedure (FDP)	ICCVAM Working Group (WG) contributed to TG development	Yes, as OECD TG 420 in 2001	OECD TG 420 (2001)	Yes, via OECD
Acute Toxic Class Method (ATC)	ICCVAM WG contributed to TG development	Yes, as OECD TG 423 in 2001	OECD TG 423 (2001)	Yes, via OECD
Acute Toxicity <i>In Vitro</i> Starting Dose Procedure, 3T3 cells	Yes, 2001 workshop report; 2006 peer review and report; recommended in 2008	Yes	OECD Guidance Document in review	OECD Guidance Document in review
Acute Toxicity In Vitro Starting Dose Procedure, NHK cells	Yes, 2001 workshop report; 2006 peer review and report; recommended in 2008	Yes	OECD Guidance Document in review	OECD Guidance Document in review

Biologics Testing

Method	ICCVAM BRDs and	U.S. Regulatory	OECD/Other	EU Regulatory
	Peer Review	Acceptance/	Adoption	Acceptance/
		Endorsement		Endorsement ²
Use of Humane Endpoints	ICCVAM agency	Yes, 9 CFR	NA	
in Animal Testing of	initiative	117.4e		
Biological Products				
Rabies Vaccine, Humane	ICCVAM agency	Yes, 9 CFR	NA	
Endpoints	initiative	117.4e		
ELISA Test for Batch	ICCVAM coordinated	Yes, per 27 CFR	NA	Published in
Potency Testing of	agency consideration	610.10; are		European
Erysipelas Vaccines		reviewed on a		Pharmacopeia
(refinement)		case-by-case basis		
Relevance of the Target	ICCVAM coordinated	Yes, per 9 CFR	NA	Published in
Animal Safety Test for	agency consideration	113.4		European
batch safety testing of				Pharmacopeia
vaccines for veterinary use				
ELISA Test for Batch	ICCVAM coordinated	Yes, per 27 CFR	NA	Published in
Potency Testing of	agency consideration	610.10; are		European
Human Tetanus Vaccines		reviewed on a		Pharmacopeia
refinement		case-by-case basis		

ToBI Test for Batch	ICCVAM coordinated	Yes, per 27 CFR	NA	Published in
Potency Testing of	agency consideration	610.10; are		European
Human Tetanus Vaccines		reviewed on a		Pharmacopeia
refinement		case-by-case basis		

Dermal Corrosivity and Irritation

Method	ICCVAM BRDs and Peer Review	U.S. Regulatory Acceptance/ Endorsement	OECD/Other Adoption	EU Regulatory Acceptance/ Endorsement ²
CORROSITEX Skin Corrosivity Test	ICCVAM peer review and report; recommended in 1999	Yes, accepted by U.S. in 2000; as OECD TG 435 in 2006	OECD Test Guideline (TG) 435 (2006)	Yes, via OECD
EpiSkin Skin Corrosivity Test	ICCVAM review and report; recommended in 2002	Yes, as OECD TG 431 in 2004	OECD TG 431 (2004)	67/548/EEC
EpiDerm Skin Corrosivity Test	ICCVAM review and report; recommended in 2002	Yes, as OECD 431 in 2004	OECD TG 431 (2004)	67/548/EEC
SkinEthic Skin Corrosivity Test	ICCVAM contributed to U.S. OECD TG review	Yes, as OECD 431 in 2004	OECD 431 (2004)	Yes, via OECD
Rat TER Skin Corrosivity Test	ICCVAM review and report; recommended in 2002	Yes, as OECD TG 430 in 2004	OECD TG 430 (2004)	67/548/EEC

Dermal Phototoxicity

Method	ICCVAM BRDs and Peer Review	U.S. Regulatory Acceptance/	OECD/Other Adoption	EU Regulatory Acceptance/
		Endorsement	•	Endorsement ²
3T3 NRU Phototoxicity	ICCVAM contributed to	Yes, as OECD TG	OECD TG 432	67/548/EEC
Test	U.S. OECD TG review	432 in 2004	(2004)	
3T3 NRU Phototoxicity	ICCVAM contributed to	Yes, as OECD TG	OECD TG 432	Yes, via OECD
Test: Application to UV	U.S. OECD TG review	432 in 2004	(2004)	
Filter Chemicals				

Immunotoxicity: Allergic Contact Dermatitis

Method	ICCVAM BRDs and Peer Review	U.S. Regulatory Acceptance/ Endorsement	OECD/Other Adoption	EU Regulatory Acceptance/ Endorsement ²
Local Lymph Node Assay for skin sensitization	ICCVAM peer review and report; recommended in 1999	Yes, accepted by U.S. in 1999; as OECD TG 429 in 2002	OECD TG 429 (2002) ISO (2002)	Yes, via OECD

Ocular Corrosivity and Irritation

Method	ICCVAM BRDs and Peer Review	U.S. Regulatory Acceptance/ Endorsement	OECD/Other Adoption	EU Regulatory Acceptance/ Endorsement ²
Bovine Corneal Opacity and Permeability (BCOP) Test Method	Yes, peer review and report; recommended in 2007	Yes, acceptance in 2008	OECD TG 437 (2009)	Yes, via OECD
Isolated Chicken Eye (ICE) Test Method	Yes, peer review and report; recommended in 2007	Yes, acceptance in 2008	OECD TG 438 (2009)	Yes, via OECD

Pyrogen Testing

Method	ICCVAM BRDs and Peer Review	U.S. Regulatory Acceptance/ Endorsement	OECD/Other Adoption	EU Regulatory Acceptance/ Endorsement ²
Human Whole Blood/Interleukin-1β <i>In</i> <i>Vitro</i> Pyrogen Test	ICCVAM peer review and report; recommended in 2008	Yes, acceptance in 2009	NA	Accepted by European Pharmacopeia
Human Whole Blood/Interleukin-1β <i>In Vitro</i> Pyrogen Test: Application of Cryopreserved Human Whole Blood	ICCVAM peer review and report; recommended in 2008	Yes, acceptance in 2009	NA	Accepted by European Pharmacopeia
Human Whole Blood/Interleukin-6 <i>In Vitro</i> Pyrogen Test	ICCVAM peer review and report; recommended in 2008	Yes, acceptance in 2009	NA	Accepted by European Pharmacopeia
Human Peripheral Blood Mononuclear Cell/Interleukin-6 <i>In</i> <i>Vitro</i> Pyrogen Test	ICCVAM peer review and report; recommended in 2008	Yes, acceptance in 2009	NA	Accepted by European Pharmacopeia
Monocytoid Cell Line Mono Mac 6/Interleukin-6 In Vitro Pyrogen Test	ICCVAM peer review and report; recommended in 2008	Yes, acceptance in 2009	NA	Accepted by European Pharmacopeia

¹Updated September 17, 2009
²Information provided by Executive Secretary, ESAC (European Centre for the Validation of Alternative Methods Scientific Advisory Committee), April 13, 2008